The Fate of the Affordable Care Act

By Bloomberg BNA, Special for  USDR

It’s no secret that Republicans are champing at the bit to quickly repeal the Affordable Care Act, but the path that will take, and how long it will take, are uncertain, according to Bloomberg BNA’s 2017 Health Care Outlook.  The special report takes a sweeping view of health care policy issues likely to dominate 2017, including potential Medicaid reform and the transition to the Trump administration, which will usher in a new cadre of agency leaders.  The outlook is available on Bloomberg Law and a complimentary copy is online at

“There is near unanimous agreement among health policy observers that there will be massive impacts to the industry when the Trump administration, which has a Republican-controlled Congress on Capitol Hill, takes office,” said Lisa Rockelli, News Director, Health Care, Bloomberg BNA.  “Dominating the agenda is the fate of the ACA, and Congress and the White House have a herculean task ahead of them to figure out a way forward to repeal the law or excise the elements of the ACA they find most objectionable while keeping insurance coverage for the approximately 20 million Americans covered by the  law.”

Highlights of the Outlook  include:

Affordable Care Act: Congressional Republicans and President-elect Donald Trump both want to fulfill campaign promises and will seek to quickly pass a law to repeal the ACA.  However, as part of the repeal bill or in separate legislation, lawmakers are likely to delay the date on which the repeal takes effect.  This would allow Congress some time to develop its replacement for the law, through which millions of Americans have obtained health care  coverage.

Pharmaceuticals and Life Sciences: Concerns about high drug prices aren’t going away in 2017.  Other top issues include the reauthorization of the Food and Drug Administration’s user fee programs, and what drug companies can say about the off-label uses of their products.  The life sciences community has trepidations about the level of support the administration will offer the research community, which may very well adversely impact genetic research, regenerative and personalized medicine.  And implementing the 21st Century Cures Law, which requires a number of new efforts designed to modernize clinical research, will dominate the research policy  landscape.

Bloomberg BNA publishes a number of 2017 outlooks across business areas that address the policies likely to shape the year ahead.  To view them all, visit

About Bloomberg  BNA

Bloomberg BNA provides legal, tax and compliance professionals with critical information, practical guidance and workflow solutions.  We leverage leading technology and a global network of experts to deliver a unique combination of news and authoritative analysis, comprehensive research solutions, innovative practice tools, and proprietary business data and analytics.  Bloomberg BNA is wholly-owned by Bloomberg L.P., the global business, financial information and news leader.  For more information, visit

SOURCE Bloomberg  BNA

All opinions expressed on USDR are those of the author and not necessarily those of US Daily Review.